NT-proBNP Qualifies as a Surrogate for Clinical End Points in Heart Failure.

Saved in:

Bibliographic Details
Title:	NT-proBNP Qualifies as a Surrogate for Clinical End Points in Heart Failure.
Authors:	Schmitt W; Pharmacometrics, Bayer AG - Pharmaceuticals, Wuppertal, Germany., Rühs H; Quantitative Pharmacology, Bayer AG - Pharmaceuticals, Wuppertal, Germany., Burghaus R; Systems Pharmacology & Medicine, Bayer AG - Pharmaceuticals, Wuppertal, Germany., Diedrich C; Systems Pharmacology & Medicine, Bayer AG - Pharmaceuticals, Wuppertal, Germany., Duwal S; Systems Pharmacology & Medicine, Bayer AG - Pharmaceuticals, Wuppertal, Germany., Eissing T; Pharmacometrics, Bayer AG - Pharmaceuticals, Wuppertal, Germany., Garmann D; Quantitative Pharmacology, Bayer AG - Pharmaceuticals, Wuppertal, Germany., Meyer M; Pharmacometrics, Bayer AG - Pharmaceuticals, Wuppertal, Germany., Ploeger B; Pharmacometrics, Bayer AG - Pharmaceuticals, Wuppertal, Germany., Lippert J; Pharmacometrics, Bayer AG - Pharmaceuticals, Wuppertal, Germany.
Source:	Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2021 Aug; Vol. 110 (2), pp. 498-507. Date of Electronic Publication: 2021 Mar 27.
Publication Type:	Journal Article; Meta-Analysis
Journal Info:	Publisher: Wiley Country of Publication: United States NLM ID: 0372741 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-6535 (Electronic) Linking ISSN: 00099236 NLM ISO Abbreviation: Clin Pharmacol Ther Subsets: MEDLINE
Database:	MEDLINE Ultimate

Description
ISSN:	1532-6535
DOI:	10.1002/cpt.2222